[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60318697D1 - Triazolderivate als tachykininrezeptor-antagonisten - Google Patents

Triazolderivate als tachykininrezeptor-antagonisten

Info

Publication number
DE60318697D1
DE60318697D1 DE60318697T DE60318697T DE60318697D1 DE 60318697 D1 DE60318697 D1 DE 60318697D1 DE 60318697 T DE60318697 T DE 60318697T DE 60318697 T DE60318697 T DE 60318697T DE 60318697 D1 DE60318697 D1 DE 60318697D1
Authority
DE
Germany
Prior art keywords
receptor antagonists
tachykinin receptor
triazone derivatives
triazone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318697T
Other languages
English (en)
Other versions
DE60318697T2 (de
Inventor
Albert Kudzovi Amegadzie
Kevin Matthew Gardinier
Erik James Hembre
Jian Eric Hong
Louis Nickolaus Jungheim
Brian Stephen Muehl
David Michael Remick
Michael Alan Robertson
Kenneth Allen Savin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60318697D1 publication Critical patent/DE60318697D1/de
Publication of DE60318697T2 publication Critical patent/DE60318697T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60318697T 2002-04-26 2003-04-22 Triazolderivate als tachykininrezeptor-antagonisten Expired - Lifetime DE60318697T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37612102P 2002-04-26 2002-04-26
US376121P 2002-04-26
PCT/US2003/010681 WO2003091226A1 (en) 2002-04-26 2003-04-22 Triazole derivatives as tachykinin receptor antagonists

Publications (2)

Publication Number Publication Date
DE60318697D1 true DE60318697D1 (de) 2008-03-06
DE60318697T2 DE60318697T2 (de) 2009-01-08

Family

ID=29270766

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60318697T Expired - Lifetime DE60318697T2 (de) 2002-04-26 2003-04-22 Triazolderivate als tachykininrezeptor-antagonisten

Country Status (31)

Country Link
US (1) US7320994B2 (de)
EP (1) EP1501809B1 (de)
JP (1) JP4559087B2 (de)
KR (1) KR100755577B1 (de)
CN (1) CN1312136C (de)
AR (1) AR039329A1 (de)
AT (1) ATE384053T1 (de)
AU (1) AU2003230829B8 (de)
BR (1) BRPI0309534B8 (de)
CA (1) CA2483159C (de)
CR (1) CR7548A (de)
CY (1) CY1107221T1 (de)
DE (1) DE60318697T2 (de)
DK (1) DK1501809T3 (de)
EA (1) EA007720B1 (de)
EC (1) ECSP045391A (de)
ES (1) ES2298513T3 (de)
HK (1) HK1073304A1 (de)
HR (1) HRP20041008B1 (de)
IL (2) IL164675A0 (de)
MX (1) MXPA04010622A (de)
MY (1) MY141559A (de)
NO (1) NO333647B1 (de)
NZ (1) NZ535886A (de)
PE (1) PE20040600A1 (de)
PL (1) PL212090B1 (de)
PT (1) PT1501809E (de)
TW (1) TWI265807B (de)
UA (1) UA79113C2 (de)
WO (1) WO2003091226A1 (de)
ZA (1) ZA200408670B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060160794A1 (en) * 2003-06-12 2006-07-20 Amegadzie Albert K Tachykinin receptor antagonists
KR100848407B1 (ko) * 2003-10-24 2008-07-28 일라이 릴리 앤드 캄파니 {2-[1-(3,5-비스-트리플루오로메틸벤질)-5-피리딘-4-일-1h-[1,2,3]트리아졸-4-일]-피리딘-3-일}-(2-클로로페닐)-메탄온의 신규 결정질 형태
WO2006083711A1 (en) * 2005-02-01 2006-08-10 Eli Lilly And Company Tachykinin receptor antagonists
WO2006106711A1 (ja) 2005-03-30 2006-10-12 Eisai R & D Management Co., Ltd. ピリジン誘導体を含有する抗真菌剤
TW200716576A (en) * 2005-06-07 2007-05-01 Shionogi & Co Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN101228137B (zh) * 2005-07-25 2010-09-29 弗·哈夫曼-拉罗切有限公司 被取代的三唑衍生物和它们作为神经激肽3受体拮抗剂的用途
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
EP2054062A1 (de) * 2006-08-18 2009-05-06 Syngenta Limited Verwendung von hppd-hemmern bei der behandlung von depression und/oder entzugserscheinungen im zusammenhang mit suchtmitteln
WO2008035726A1 (fr) 2006-09-21 2008-03-27 Eisai R & D Management Co., Ltd. Dérivé de pyridine substitué par un cycle hétéroaryle, et agent antifongique le comprenant
JP5443168B2 (ja) * 2006-12-20 2014-03-19 イーライ リリー アンド カンパニー {2−[1−(3,5−ビス−トリフルオロメチル−ベンジル)−5−ピリジン−4−イル−1h−[1,2,3]トリアゾール−4−イル]−ピリジン−3−イル}−(2−クロロフェニル)−メタノンの調製において有用な新規の中間体及び方法
US8110588B2 (en) 2007-08-08 2012-02-07 Neurosearch A/S 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
GB0722077D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US20110086834A1 (en) * 2008-06-26 2011-04-14 Amgen Inc. Alkynyl alcohols as kinase inhibitors
GB0823002D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isoxazoles derivatives with plant growth regulating properties
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
EP3730140A1 (de) * 2015-03-04 2020-10-28 Vanda Pharmaceuticals Inc. Verfahren zur behandlung mit tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
EP3464271B1 (de) 2016-05-31 2020-05-13 Kalvista Pharmaceuticals Limited Pyrazol-derivate als plasma-kallikrein-inhibitoren
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
KR20200054232A (ko) 2017-09-13 2020-05-19 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
IL274541B2 (en) 2017-11-17 2024-10-01 Vanda Pharmaceuticals Inc A method for treating diseases of the digestive tract using Tradifitant
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
SI3716952T1 (sl) 2017-11-29 2022-04-29 Kalvista Pharmaceuticals Limited Farmacevtske oblike, ki obsegajo zaviralec plazemskega kalikreina
US20210015834A1 (en) 2018-02-26 2021-01-21 Ospedale San Raffaele S.R.L. Nk-1 antagonists for use in the treatment of ocular pain
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
JP7468964B2 (ja) * 2018-09-28 2024-04-16 バンダ・ファーマシューティカルズ・インコーポレイテッド 動揺病におけるトラジピタントの使用
EP3890735A1 (de) 2018-12-03 2021-10-13 Vanda Pharmaceuticals Inc. Verfahren zur behandlung mit tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN115052599A (zh) 2020-02-25 2022-09-13 万达制药公司 以川地匹坦对特应性皮炎的改进治疗
US20230134843A1 (en) 2020-03-11 2023-05-04 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
EP4125811A1 (de) 2020-03-26 2023-02-08 Vanda Pharmaceuticals Inc. Behandlung von infektionen der unteren atemwege mit tradipitant
WO2021198255A1 (en) 2020-04-03 2021-10-07 Nerre Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
MX2022014901A (es) 2020-06-02 2023-01-18 Nerre Therapeutics Ltd Antagonistas del receptor de neuroquinina (nk)-1 para su uso en el tratamiento de condiciones de fibrosis pulmonar promovidas por lesion mecanica a los pulmones.
CN111662235B (zh) * 2020-06-23 2023-12-22 黄淮学院 一种苯甲酰基哒嗪衍生物及其制备方法
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2024138040A1 (en) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant
WO2024223617A1 (en) * 2023-04-24 2024-10-31 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
AU7947594A (en) * 1993-10-27 1995-05-22 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
AU2633897A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Solid phase and combinatorial synthesis of substituted 1,2,3-triazoles and of arrays of substituted 1,2,3-triazoles
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
EP0915880B1 (de) 1996-07-24 2007-10-10 Bristol-Myers Squibb Pharma Company Azolotriazine und pyrimidine
WO1999007677A1 (en) 1997-08-06 1999-02-18 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
CO5261559A1 (es) * 1999-12-17 2003-03-31 Schering Corp Antagonistas de neurokinina selectivos
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
DE10036818A1 (de) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
JP2002123925A (ja) 2000-10-13 2002-04-26 Fuji Photo Film Co Ltd 磁気記録媒体
US7179804B2 (en) * 2002-04-26 2007-02-20 Eli Lilly And Company Tachykinin receptor antagonists

Also Published As

Publication number Publication date
EA007720B1 (ru) 2006-12-29
NO333647B1 (no) 2013-07-29
KR100755577B1 (ko) 2007-09-12
JP4559087B2 (ja) 2010-10-06
US20050239786A1 (en) 2005-10-27
CR7548A (es) 2006-12-01
BR0309534A (pt) 2005-02-01
NZ535886A (en) 2007-07-27
KR20040104634A (ko) 2004-12-10
JP2005536458A (ja) 2005-12-02
CY1107221T1 (el) 2012-11-21
BRPI0309534B8 (pt) 2021-05-25
AU2003230829B8 (en) 2008-12-11
ZA200408670B (en) 2005-10-26
DE60318697T2 (de) 2009-01-08
UA79113C2 (en) 2007-05-25
HK1073304A1 (en) 2005-09-30
WO2003091226A1 (en) 2003-11-06
CA2483159C (en) 2010-08-10
EP1501809B1 (de) 2008-01-16
AU2003230829A1 (en) 2003-11-10
AR039329A1 (es) 2005-02-16
BRPI0309534B1 (pt) 2017-11-07
NO20045120L (no) 2004-12-07
TW200306824A (en) 2003-12-01
TWI265807B (en) 2006-11-11
US7320994B2 (en) 2008-01-22
EA200401431A1 (ru) 2005-06-30
HRP20041008B1 (hr) 2012-10-31
CN1312136C (zh) 2007-04-25
MXPA04010622A (es) 2005-01-25
DK1501809T3 (da) 2008-05-13
EP1501809A1 (de) 2005-02-02
HRP20041008A2 (en) 2004-12-31
IL164675A0 (en) 2005-12-18
CN1646502A (zh) 2005-07-27
CA2483159A1 (en) 2003-11-06
ECSP045391A (es) 2005-01-03
ES2298513T3 (es) 2008-05-16
PE20040600A1 (es) 2004-09-15
PT1501809E (pt) 2008-03-18
ATE384053T1 (de) 2008-02-15
IL198122A0 (en) 2009-12-24
PL212090B1 (pl) 2012-08-31
PL373504A1 (en) 2005-09-05
AU2003230829B2 (en) 2008-12-04
MY141559A (en) 2010-05-14

Similar Documents

Publication Publication Date Title
DE60318697D1 (de) Triazolderivate als tachykininrezeptor-antagonisten
ATE328871T1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
NO20051871D0 (no) Opioid reseptorantagonister
ATE413400T1 (de) Cgrp-rezeptorantagonisten
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
ATE288898T1 (de) Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
ATE525378T1 (de) Himbacinanaloga als thrombinrezeptorantagonisten
ATE461191T1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
DE602005004011D1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
ATE322496T1 (de) 4-phenylpyridin-derivate als neurokinin-1- rezeptor-antagonisten
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
ATE286022T1 (de) Naphthalin-carboxamide als tachykinin rezeptorantagonisten
DE50100358D1 (de) Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
ATE370114T1 (de) Zwitterionische tachykinin-rezeptor-antagonisten
ATE488519T1 (de) Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
ATE338043T1 (de) 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten
ATE504300T1 (de) Harnstoffderivate als il-8-rezeptorantagonisten
ATE495168T1 (de) Heteroarylsubstituierte imidazolderivate als glutamatrezeptorantagonisten
ATE528291T1 (de) Cyclopropylderivate als nk3 rezeptor-antagonisten
NO20055725D0 (no) Glutamatreseptorantagonister som neurobeskyttende midler
DE60314238D1 (de) Kondensierte, bicyclische pyridinderivate als antagonisten des tachykininrezeptors
ATE305005T1 (de) Piperazinderivative als tachykinin antagonisten
DE602004018527D1 (de) Furanderivate als ep4-rezeptorantagonisten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN